USANA Health Sciences (USNA) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales declined 6.2% year-over-year to $200.2 million, with diluted EPS at $0.56, down from $0.59 in Q3 2023, and active customers decreased to 452,000.

• Net earnings for Q3 2024 were $10.6 million, down from $11.3 million in Q3 2023, reflecting lower sales and higher operating expenses.

• Management cited continued headwinds in key markets, especially China, but highlighted progress on strategic initiatives, product innovation, and global expansion, including India.

• The company operates in 25 markets, with about 90% of net sales generated outside the US, and maintains a low capital intensity business model with strong cash flow and no debt.

• Increased promotional activity is planned for Q4 to support business momentum, with updated fiscal 2024 guidance reflecting these efforts.

Financial highlights

• Q3 2024 net sales were $200.2 million, down 6.2% year-over-year; net earnings were $10.6 million, and diluted EPS was $0.56.

• Gross margin for Q3 2024 was 80.4%, up from 80.1% in Q3 2023, driven by lower material costs and favorable market mix.

• Cash and cash equivalents as of Q3 2024 were $365 million, with no debt.

• Free cash flow for the trailing twelve months was $74 million, with a free cash flow margin of 9%.

• Operating cash flow for the first nine months of 2024 was $55.2 million, up from $44.6 million in the prior-year period.

Outlook and guidance

• Fiscal 2024 net sales guidance is $850 million, with diluted EPS of $2.45 and operating margin of 8.5%.

• Fourth quarter guidance includes higher promotional spending, expected to impact margins and EPS.

• Management does not expect recent stimulus in China to impact near-term results.

• Product pipeline for 2025 is robust, with significant upgrades and new launches planned, especially in the nutritionals category.

• Remediation of material weaknesses in IT general controls is ongoing, with completion expected before year-end 2024.